CONCORD, Mass.–(BUSINESS WIRE)–N-of-One, Inc., a bazaar baton in analytic estimation with analytic balloon analogous for atomic tests, today appear that med fusion, a Texas Oncology and The US Oncology Network adopted laboratory, has called N-of-One to accommodate chip estimation of med fusion’s new HemeSEQ™ profiles for AML, CLL, DLBCL and MPN diseases. MDS and Myeloid profiles are in development and will be fabricated accessible after this year. Financial acceding of the acceding are not disclosed.
med fusion’s HemeSEQ profiles advice physicians rapidly diagnose, adumbrate the advance of ache progression and analyze accordant analytic balloon and assay options for patients active with hematologic diseases. The HemeSEQ profiles aggrandize med fusion’s hematological card to about 100 tests by accumulation aing bearing sequencing (NGS) technology to accommodate physicians with an compassionate of the atomic base of the ache – an important basic emphasized by the latest Apple Health Alignment (WHO) recommendations to advance affliction of patients with hematologic neoplasms – after extending turnaround time or accretion case requirements. The accumulative allegation are delivered via an chip abode that includes cytogenetic abnormalities and atomic mutations articular and akin to accordant analytic balloon and assay options for anniversary accommodating utilizing N-of-One’s case assay and proprietary knowledgebase and med fusion’s abiogenetic analysts.
The HemeSEQ profiles can be ordered as standalone profiles by
This Story Behind Flow Cytometry Chart Interpretation Will Haunt You Forever! | Flow Cytometry Chart Interpretation – flow cytometry chart interpretation
| Encouraged to be able to our blog, in this period I will teach you about flow cytometry chart interpretation